AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02827370 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Dietary Intervention
Description: Receive dietary counseling
Study NCT01844986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib 300mg tablets
Description: Olaparib/placebo tablets p.o 300mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
Study NCT01844986 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olaparib 300mg tablets
Description: Olaparib/placebo tablets p.o 300mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
Study NCT03142334 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT03142334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion
Study NCT04260607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Experimental Procedure~1. Baseline evaluation of suicidal severity (BSSI) \& degree of depressive symptoms (MADRS-S) will be evaluated through self-administered questionnaires.~2. The experimental and placebo arms will receive a single dose of IV ketamine, 0.5 mg/kg in 100 cc NS or 100 cc of NS infused over 40 minutes.~3. Post ketamine re-evaluation of outcome measures at four and twenty-four hours will determine clinical effectiveness of ketamine intervention~4. Inspection of admission and transfer time provides time measurement for LOS. This secondary measure is needed to determine efficiency of intervention.~5. Post ketamine re-evaluation of outcome measure at one-week post infusion will elucidate ketamine's durability of effect.
Study NCT04260607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Experimental Procedure~1. Baseline evaluation of suicidal severity (BSSI) \& degree of depressive symptoms (MADRS-S) will be evaluated through self-administered questionnaires.~2. The placebo arms will receive a single dose of 100 cc of NS infused over 40 minutes.~3. Post Placebo infusion re-evaluation of outcome measures at four and twenty-four hours~4. Inspection of admission and transfer time provides time measurement for LOS. This secondary measure is needed to determine efficiency of intervention.~5. Post Normal Saline re-evaluation of outcome measure at one-week post infusion.
Study NCT03254641 — intervention group
Intervention type: DRUG
Intervention: human chorionic gonadotropin
Description: 5000 IE times one
Study NCT03680508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSR-022 and TSR-042
Description: immunotherapy
Study NCT03251664 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Food groups consumed
Study NCT01923168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alpelisib
Description: BYL719 + Letrozole
Study NCT01923168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buparlisib
Description: BKM120 + Letrozole
Study NCT01923168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (of BYL719 or BKM120) + Letrozole
Study NCT01466595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Participant were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.
Study NCT00487435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol (CG5503) Extended Release (ER)
Description: 100, 150, 200, 250 mg oral tablet twice daily for 52 weeks
Study NCT01633281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Ten sessions of acupuncture at 2x per week over 5 weeks will be given to patients. The acupuncture points include a standard set of obligatory points and additional points based on symptoms.
Study NCT02827682 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angel-6000D Multiparameter Anesthesia Monitor (IoC)
Description: The Angel-6000D Multiparameter Anesthesia Monitor, Shenzhen Weihaokang Medical Technology Co., Ltd, Guangdong, China
Study NCT02827682 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: BIS VISTA Monitor (BIS)
Description: BIS VISTA Monitor, Covidien, Changchun city shi jia trade co., Ltd, Changchun, China
Study NCT05276986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DOMS protocol
Description: For a maximum repetition of the trunk muscles, two measurements were made with a 45-second rest interval.The values were recorded in Newtons by taking the maximum value of the two repetitions measured. DOMS was formed by eccentric contraction with 80% of this determined value.To generate DOMS in the trunk, participants were seated on the bench with the knees flexed at 90° and the soles of the feet in full contact with the floor, keeping the weight at 80% of the predetermined maximum repetition.The participants were asked to perform trunk extension with eccentric contraction of the trunk in 5 seconds, and trunk flexion with concentric contraction in 3 seconds.Two-minute rests between sets and 45-second rests between repetitions were given.The date and time of the created DOMS were recorded and the measurements were repeated at the 24th and 48th hours.
Study NCT00873990 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Total etch bonding agent (5th generation)
Description: Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for etch and rinse bonding system (two step bonding agent) will be treated with 37% phosphoric acid (Total Etch Ivoclar Vivadent) for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved.~Adper Single Bond 2 (3M ESPE) will be applied to occlusal fissure using applicator brushes followed by curing for 10 seconds. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds.
Study NCT00873990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self etch (7th generation ) bonding agent
Description: For teeth selected for application of self etching bonding agent (Adper Easy Bond 3 M), the bonding agent will be applied to occlusal surface with microbrushes and will be left undisturbed for 20 seconds followed by air drying for 5 seconds and then will be light cured for 10 seconds. Fissure sealant (Clinpro 3M ESPE) will be applied in a similar manner as for etch and rinse group and light cured.
Study NCT00582205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Cisplatin IP
Description: Paclitaxel 135 mg/m2 IV (3-hr infusion) on Day 1, Cisplatin 50 mg/m2 IP on Days 1 and 8, Repeat every 3 weeks for 6 cycles
Study NCT04327401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone administration for 10 consecutive days after randomization.
Study NCT03173651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Williams airway
Description: This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group W
Study NCT03173651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Guedle's airway
Description: This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group G
Study NCT03173651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LMA MADgic airway
Description: This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group M
Study NCT04044027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S.P.A.R.K (Speaking to the Potential, Ability and Resilience inside Kids) Teen Pregnancy Prevention and Mentoring
Description: S.P.A.R.K is a curriculum-based group intervention for youth ages 11-17 living in out-of-home foster care. The curriculum consists of 23 topical lessons made up of a combination of educational and interactive activities on each topic. The curriculum covers four Adult Preparation Subjects (healthy relationships, educational and career success, healthy life skills, adolescent development) as well as mentoring, bully prevention, emotional competency, self-efficacy, communication, conflict resolution, and pregnancy prevention.
Study NCT03210662 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo EBRT
Study NCT03210662 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT00986102 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: doripenem
Description: 500mg vial by injection every 8 hours for 5 to 14 days
Study NCT04778072 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate 14mg once daily
Description: ACTIVE IRON™ (ferrous sulfate) 14 mg elemental iron once daily with matching placebo
Study NCT04778072 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate 25mg once daily
Description: ACTIVE IRON™ (ferrous sulfate) 25 mg elemental iron once daily with matching placebo
Study NCT03671148 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for risankizumab administered by subcutaneous (SC) injection
Study NCT03671148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for risankizumab administered by subcutaneous (SC) injection
Study NCT03671148 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Risankizumab
Description: Risankizumab administered by subcutaneous (SC) injection
Study NCT03671148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Risankizumab administered by subcutaneous (SC) injection
Study NCT02060188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT02060188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT02060188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Specified dose on specified days
Study NCT02060188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Specified dose on specified days
Study NCT02060188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986016
Description: Specified dose on specified days
Study NCT02615691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEGylated Recombinant Factor VIII
Description: Polyethylene glycol (PEG)-ylated full-length recombinant FVIII (rFVIII).
Study NCT02615691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ITI
Description: Immune tolerance induction therapy
Study NCT04401475 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SOC plus 15mg/kg EB05 IV
Description: Standard of care plus single IV infusion of 15mg/kg of EB05.
Study NCT04401475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SOC plus Placebo IV
Description: Standard of care plus a single IV infusion of placebo.
Study NCT04572841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441344
Description: Pharmaceutical form: solution for injection~Route of administration: intravenous or subcutaneous
Study NCT04572841 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution for injection~Route of administration: intravenous or subcutaneous
Study NCT03093870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varlitinib
Description: Varlitinib:300mg, oral tablets, twice daily. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
Study NCT03093870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: 1000mg/m2, oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
Study NCT03093870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2, oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
Study NCT03093870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Varlitinib)
Description: oral tablets, twice daily. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death
Study NCT04082676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine spinal
Description: In this group patient will receive intrathecal hyperbaric bupivacaine based on patients height and weight according to Harten chart with 10 μg of fentanyl (0.1 ml)
Study NCT04082676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric bupivacaine spinal
Description: In this group will receive intrathecal hyperbaric bupivacaine based on patients height (0.06mg/cm) with 10 μg of fentanyl (0.1 ml)
Study NCT01477411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21
Description: The maximum dose of PA21 will be 15.0 g/day.
Study NCT01477411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: The maximum dosage of Digoxin will be 0.5 mg/day
Study NCT01104337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets twice a day along with two matching placebo tablets once daily
Study NCT01104337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paracetamol
Description: Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets three times a day
Study NCT01104337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment consisted of two matching placebo tablets three times a day.
Study NCT01572662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine monophosphate
Description: 40 mg/m2 by vein on Days -6 through -3.
Study NCT01572662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: First two doses of Busulfan, 80 mg/m2 administered as an outpatient or as an inpatient to facilitate for this pharmacokinetically directed therapy. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies.
Study NCT01572662 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Fresh or cryopreserved bone marrow or peripheral blood progenitor cells infused on Day 0.
Study NCT01572662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Starting dose of 0.015 mg/kg (ideal body weight) as 24 hour continuous infusion daily adjusted to achieve therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) present.
Study NCT01572662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.
Study NCT01572662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 \* 10/L for 3 consecutive days.
Study NCT04637139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vebicorvir (VBR)
Description: 300mg Vebicovir containing 2 µCi \[14C\]VBR.
Study NCT00408616 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grazax-R
Description: Grass tablet, 75.000 SQ per day for one year
Study NCT00408616 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Grazax Placebo
Description: Grazax Placebo, 0 SQ tablet per day for one year
Study NCT03640741 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopy
Description: The studies are carried out on patients who undergoes gynecological procedure that involves laparoscopy.
Study NCT02671630 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A community-based computerized cognitive training program
Description: The computer training games included: 1) a phonological loop to train the participants to choose correct song from a list of different songs which can be categorized as people, nature, and musical instrument. The difficulty level progressed from choosing one from two to choosing one from three songs; 2) a visual-spatial sketchpad to train the participants to remember and find the same graphs including vegetable, fruits, daily necessity, and numbers. The difficulty level progressed from finding one pair to three pairs of similar graphs; 3) a central executive system to train the participants to execute dual tasks including conducting dual memory, calculating while listening to music, making phone calls, and matching medication at correct time.
Study NCT00965757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-614
Description: T-614 is administered twice daily in combination with methotrexate. The daily dose of T-614 is 25 mg for the first 4 weeks and 50 mg for subsequent weeks.
Study NCT00965757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered twice daily in combination with methotrexate. In placebo group, patients will receive T-614 after completing 28 weeks of treatment.
Study NCT01044537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match PF-04937319 will be provided.
Study NCT01044537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04937319
Description: The initial planned dosing schedule is: 10, 30, 100, 200, and 400 mg, with one cohort to be determined. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as a single oral dose as a powder-in-capsule (PIC) formulation. PF-04937319 will be supplied as 10 mg and 80 mg (and potentially 1 mg) PIC.
Study NCT02747680 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: hypoglycemia (low blood sugar) in MRI
Description: hypoglycemia (low blood sugar) in MRI
Study NCT00873587 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chest tube pull on inspiration
Description: Pull chest tube on Inspiration
Study NCT02594956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: no nasogastric tube
Study NCT02594956 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasogastric tube
Study NCT00873587 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Expiration
Description: Pull chest tube on Expiration
Study NCT01287351 — intervention group
Intervention type: DRUG
Intervention: extra-fine hydrofluoroalkane beclometasone dipropionate
Study NCT01287351 — intervention group
Intervention type: DRUG
Intervention: Fluticasone propionate
Study NCT03892915 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: evidence-based depression treatment
Description: We will use a stepped care approach to depression treatment. Participants with clinical depression (defined as PHQ-9>9) will be offered either Problem Solving Therapy (PST) or Antidepressant Therapy (ADT), but those with moderate to moderately severe depression will be recommended PST, while those with severe depression will be recommended ADT. Participants with subthreshold depressive symptoms (PHQ-9: 5-9) will receive depression psychoeducation and continued depressive monitoring.
Study NCT04016402 — intervention group
Intervention type: DEVICE
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Clinical transcranial magnetic stimulation administered as part of usual care for the study population
Study NCT01115621 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glutenfree diet during the first year of life
Description: Glutenfree diet during the first year of life
Study NCT04656548 — intervention group
Intervention type: DEVICE
Intervention: HydroPICC
Description: PICC lines
Study NCT00928005 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss diet
Description: The weight loss diet will follow the American Diabetes Association guidelines and be nutritionally balanced with a reduced saturated fat content.
Study NCT00928005 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss diet plus exercise
Description: The supervised exercise training sessions will take place three times a week for 6 months. Each session will last 1 to 1 ½ hours and will include aerobic exercise and weight training.
Study NCT02314247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: 20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-4 of each 4-week cycle (Protocol V.3.0).~20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-3 of each 4-week cycle (Protocol V.\<3.0).~Number of Cycles: up to 12 but there is no maximal duration for treatment.
Study NCT03951415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PARP inhibitor and Anti-PD-L1
Description: olaparib tablets 300mg twice daily orally and durvalumab 1500mg by IV infusion every 4 weeks